Cargando…

Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review

OBJECTIVE: This review aimed to assess the quality of available evidence on the economic evaluations of immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) and provide evidence to improve the efficiency of healthcare resources. MATERIALS AND METHODS: Literature search wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Na, Zheng, Huanrui, Zheng, Bin, Chen, Chaoxin, Cai, Hongfu, Liu, Maobai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297344/
https://www.ncbi.nlm.nih.gov/pubmed/32606944
http://dx.doi.org/10.2147/CMAR.S248020
_version_ 1783546984628486144
author Li, Na
Zheng, Huanrui
Zheng, Bin
Chen, Chaoxin
Cai, Hongfu
Liu, Maobai
author_facet Li, Na
Zheng, Huanrui
Zheng, Bin
Chen, Chaoxin
Cai, Hongfu
Liu, Maobai
author_sort Li, Na
collection PubMed
description OBJECTIVE: This review aimed to assess the quality of available evidence on the economic evaluations of immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) and provide evidence to improve the efficiency of healthcare resources. MATERIALS AND METHODS: Literature search was performed using some electronic databases (PubMed, Embase and Cochrane Central Register of Controlled Trials). Final search was performed in December 2019. Study characteristics and results were recorded and compared. The quality of the studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. We did not elaborate the restrictions on the target population. We included patients with squamous or non-squamous NSCLC and metastatic or advanced cancer. RESULTS: Of 98 papers considered, 21 were chosen for this review. Most of them are cost-effectiveness analysis. Comparative regimens consisted of either immune checkpoint inhibitor monotherapy, immune checkpoint inhibitor plus chemotherapy, or chemotherapy alone. Fourteen, four, and three studies were about pembrolizumab, nivolumab, and atezolizumab, respectively. The methods mostly used in these studies were modeling and sensitivity analysis. All studies used quality-adjusted life year (QALY) and life years (LY) as outcomes. Most studies were conducted in high-income countries. Based on the willingness to pay threshold, atezolizumab, and pembrolizumab were found to be cost-effective in one and 10 studies, respectively. None of the studies concluded that nivolumab was cost-effective. For quality assessment, all studies fulfilled more than 50% of the CHEERS checklist. CONCLUSION: The included studies indicated that pembrolizumab regimens are cost-effective as first-line treatment for patients with NSCLC in developed countries. Nivolumab and atezolizumab are likely to be cost-effective as second-line treatment but not as first-line treatment.
format Online
Article
Text
id pubmed-7297344
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72973442020-06-29 Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review Li, Na Zheng, Huanrui Zheng, Bin Chen, Chaoxin Cai, Hongfu Liu, Maobai Cancer Manag Res Review OBJECTIVE: This review aimed to assess the quality of available evidence on the economic evaluations of immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) and provide evidence to improve the efficiency of healthcare resources. MATERIALS AND METHODS: Literature search was performed using some electronic databases (PubMed, Embase and Cochrane Central Register of Controlled Trials). Final search was performed in December 2019. Study characteristics and results were recorded and compared. The quality of the studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklists. We did not elaborate the restrictions on the target population. We included patients with squamous or non-squamous NSCLC and metastatic or advanced cancer. RESULTS: Of 98 papers considered, 21 were chosen for this review. Most of them are cost-effectiveness analysis. Comparative regimens consisted of either immune checkpoint inhibitor monotherapy, immune checkpoint inhibitor plus chemotherapy, or chemotherapy alone. Fourteen, four, and three studies were about pembrolizumab, nivolumab, and atezolizumab, respectively. The methods mostly used in these studies were modeling and sensitivity analysis. All studies used quality-adjusted life year (QALY) and life years (LY) as outcomes. Most studies were conducted in high-income countries. Based on the willingness to pay threshold, atezolizumab, and pembrolizumab were found to be cost-effective in one and 10 studies, respectively. None of the studies concluded that nivolumab was cost-effective. For quality assessment, all studies fulfilled more than 50% of the CHEERS checklist. CONCLUSION: The included studies indicated that pembrolizumab regimens are cost-effective as first-line treatment for patients with NSCLC in developed countries. Nivolumab and atezolizumab are likely to be cost-effective as second-line treatment but not as first-line treatment. Dove 2020-06-12 /pmc/articles/PMC7297344/ /pubmed/32606944 http://dx.doi.org/10.2147/CMAR.S248020 Text en © 2020 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Li, Na
Zheng, Huanrui
Zheng, Bin
Chen, Chaoxin
Cai, Hongfu
Liu, Maobai
Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
title Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
title_full Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
title_fullStr Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
title_full_unstemmed Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
title_short Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
title_sort economic evaluations of immune checkpoint inhibitors for patients with non-small cell lung cancer: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297344/
https://www.ncbi.nlm.nih.gov/pubmed/32606944
http://dx.doi.org/10.2147/CMAR.S248020
work_keys_str_mv AT lina economicevaluationsofimmunecheckpointinhibitorsforpatientswithnonsmallcelllungcancerasystematicreview
AT zhenghuanrui economicevaluationsofimmunecheckpointinhibitorsforpatientswithnonsmallcelllungcancerasystematicreview
AT zhengbin economicevaluationsofimmunecheckpointinhibitorsforpatientswithnonsmallcelllungcancerasystematicreview
AT chenchaoxin economicevaluationsofimmunecheckpointinhibitorsforpatientswithnonsmallcelllungcancerasystematicreview
AT caihongfu economicevaluationsofimmunecheckpointinhibitorsforpatientswithnonsmallcelllungcancerasystematicreview
AT liumaobai economicevaluationsofimmunecheckpointinhibitorsforpatientswithnonsmallcelllungcancerasystematicreview